BioCentury
ARTICLE | Company News

Chinese PE firm to acquire Epigenomics

April 26, 2017 10:38 PM UTC

A subsidiary of Chinese private equity firm Cathay Fortune International Co. Ltd. will acquire molecular diagnostics company Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) for €7.52 per share, or about €171 million ($185.6 million) in cash.

The subsidiary, Blitz F16-83 GmbH, will change its name to Summit Hero Holding GmbH. Epigenomics' partner and largest shareholder BioChain Institute Inc. (Newark, Calif.) will own an indirect stake in Summit...

BCIQ Target Profiles

Septin 9 (SEPT9)